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Background. Renal dialysis has recently been recognised as a risk factor for lower limb amputation (LLA). However, exact rates
and associated risk factors for the LLA are incompletely understood. Aim. Prevalence and risk factors of LLA in end-stage renal
failure (ESRF) subjects on renal dialysis were investigated from the existing literature.Methods. Published data on the subject were
derived from MEDLINE, PubMed, and Google Scholar search of English language literature from January 1, 1980, to July 31, 2015,
using designated key words. Results. Seventy studies were identified out of which 6 full-text published studies were included in
this systematic review of which 5 included patients on haemodialysis alone and one included patients on both haemodialysis and
peritoneal dialysis. The reported findings on prevalence of amputation in the renal failure on dialysis cohort ranged from 1.7% to
13.4%. Five out of the six studies identified diabetes as the leading risk factor for amputation in subjects with ESRF on renal dialysis.
Other risk factors identified were high haemoglobin A1c, elevated c-reactive protein, and low serum albumin. Conclusions. This
review demonstrates high rate of LLA in ESRF patients receiving dialysis therapy. It has also identified diabetes and markers of
inflammation as risk factors of amputation in ESRF subjects on dialysis.
1. Introduction
End-stage renal failure, defined as nonreversible kidney
damage requiring replacement therapy [1], is a recognised
risk factor for peripheral artery disease leading to nonhealing
ulcers and lower limb amputation (LLA) [2–6].The aetiology
of ESRF such as diabetes may be associated with complex
vascular dysfunction and widespread organ involvement
including cardiovascular and musculoskeletal systems, the
two being the most important cause of morbidity and
mortality in patients with ESRF on haemodialysis [1, 2, 7].
The prevalence of diabetes globally, as reported by the
International Diabetes Federation in 2015, was 415 million
(8.3% of the world’s adult population) and is projected to
alarmingly rise to 642 million by 2040, a significant rise over
a small period of time [8, 9]. Diabetes is a leading cause of
foot ulcer and renal failure amongst others [10]. In the case of
foot ulcer, the combination of vascular insufficiency and local
infection worsens the prognosis resulting in life threatening
sepsis, LLA, and death [11–14]. Furthermore, the prevalence
of foot complications in general is considerably higher in
patients with diabetes and ESRF as compared to patients
with diabetes without ESRF [5, 6, 13, 14]. It is known that
LLA increases patient disability, decreases quality of life, and
contributes to high morbidity, mortality, and health care
costs [15–17] yet not much information on the extent of the
problems is known worldwide.
Although various studies investigating the outcome of
foot complications in patients with diabetes have been
reported, prevalence of lower limb amputation in subjects on
renal dialysis remains poorly recognised [6, 18]. Furthermore,
clinical and biochemical features accounting for the high
rate of LLA in subjects on renal dialysis are inconclusive.
This systematic review aimed to critically appraise published
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studies which have assessed LLA as an outcome in patients
with ESRF on dialysis and to determine prevalence and risk
factors associated with LLA in the study population.
2. Methods
2.1. Protocol and Focus. This systematic review was per-
formed with the standardised written protocol that followed
the Preferred Reporting Items for Systematic Reviews and
Meta-Analyses (PRISMA) guidelines [25].The review focuses
on studies which assessed the prevalence and identified risk
factors for lower limb amputation in patients who have
received renal dialysis.
2.2. Search Criteria. A search strategy was formulated to
identify studies in which LLA was assessed in patients with
ESRF on dialysis. Databases from MEDLINE/PubMed (US
National Library of Medicine, Bethesda, MD, USA) and
Google Scholar (Google, Mountain View, CA, USA) were
searched from January 1, 1980, to July 31, 2015. Keyword sets
combined “diabetes” or “diabetic ulcer” or “diabetic foot” and
“amputation” and “renal dialysis”.
2.3. Eligibility Criteria. Tobe eligible, studieswere required to
focus on amputation as an outcome in ESRF patients on renal
dialysis. For inclusion, studies had to be published before July
31, 2015. Publications were restricted to human studies and
those published in English.There was no restriction on study
size. For the inclusion of publications, the studies needed to
be full articles which investigated patients on haemodialysis
and/or peritoneal dialysis as a cohort and required recording
of the prevalence and/or the risk factors associated with
amputation as an outcome in this cohort.
Publications were excluded from this systematic review if
theywere review articles, looked at traumatic/neoplastic, only
upper extremity/penile amputation as outcomes, compared
prognosis of different interventions, and included only a
subgroup of dialysis patients in the study (such as patients
with diabetes on renal dialysis and patients on renal dialysis
who had peripheral artery bypass).
2.4. Data Extraction. Data from the identified studies was
extracted by one author. Any uncertainty was resolved by
discussion between authors. Data extraction from eligible
literature included information regarding geographical loca-
tion, sample size, mean age, percentage of male patients,
mean time on dialysis, diabetes mellitus, smoking history,
hypertension, coronary artery disease, amputation, and risk
factors (RR, OR,HR, RH,𝑝 values, and confidence intervals).
Data was transcribed into an excel data collection sheet.
3. Results
3.1. Search Results. Seventy published studies were identified
as per the abovementioned search criteria (Figure 1). Fifty
studies were excluded due to various reasons such as lack
of investigating lower limb amputation as an outcome, dial-
ysis/renal replacement/renal replacement therapy/end-stage
renal failure/renal failure/end-stage kidney disease/kidney
failure not being mentioned in the title, and comparing
prognosis and outcomes of various pharmacological and
surgical interventions. Abstracts were critically screened for
the 20 remaining studies out of which another 14 were
excluded due to being review articles (𝑛 = 6); being case
studies (𝑛 = 2); only including a subset of dialysis patients
(𝑛 = 2); not including dialysis patients (𝑛 = 1); assessing
vascular changes in amputated limbs as an outcome (𝑛 = 1);
assessing prognosis of percutaneous transluminal angioplasty
as an outcome (𝑛 = 1); inability to access full text (𝑛 = 1).
In all, 6 full-text publications were reviewed as detailed in
Figure 1.
3.2. Characteristics of Included Studies and Subjects. Five out
of the six studies included patients on haemodialysis [19–23]
and one study included both haemodialysis and peritoneal
dialysis patients [24]. There was no study that only included
peritoneal dialysis patients.
As for the outcomes, two of the studies investigated
only amputation in particular [19, 22] and the remaining
four explored other outcomes as well such as foot problems,
peripheral vascular disease related procedures, myocardial
infarction, and mortality [20, 21, 23, 24]. The data related to
these outcomes was presented separately in all these studies;
therefore, it was possible to assess data specific to amputation
by itself. There was marked variation in sample size between
studies. All studies included at least 100 subjects (Table 1).
Two studies included between 100 and 500 patients (𝑛 = 271,
𝑛 = 232) [20, 21], three studies had between 1000 and 5000
subjects (𝑛 = 1513, 𝑛 = 1041, and 𝑛 = 3272) [19, 23, 24], and
one study had 29838 subjects [22]. Most publications sourced
participants from hospital or dialysis clinics, apart from one
study that was conducted on patients from a nursing home
setting [21]. Three of the studies recruited participants from
single centres [20, 21, 23] and three frommultiple centres [19,
22, 24]. Populations examined also varied between studies.
Three studies focused on American patients [19, 21, 24].
Single studies recruited patients from Japan [23] and Canada
[20]. One study included patients from around the world
including 12 countries [22].Three studies extracted data from
larger studies such as the Choices for Healthy Outcomes in
Caring for End-Stage Renal Disease (CHOICE) [24], Dialysis
Outcomes and Practice Patterns Study (DOPPS) [22], and the
ESRF Core Indicator/Clinical Performance Measure (CPM)
Project [19].
All the studies were consistent in defining their inclusion
criteria of patients on dialysis therapy; they all identified that
patients with ESRF were placed on renal dialysis as a form
of renal replacement therapy, that being either haemodialysis
or peritoneal dialysis. The studies defined the endpoint
being development of amputation, which could have been
performed when uncontrollable limb infection existed even
after undergoing revascularization and/ormedical treatment.
One publication specifically defined nontraumatic lower limb
amputation and excluded digital amputation as one of the
primary outcomes that were investigated [24]. Only one
study specifically defined major amputation as above-the-
knee amputation [23].
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Studies identified through database 
search
(n = 70)
Titles screened
(n = 70)
Records excluded
(n = 50)
Reasons: lower limb amputation not an 
outcome (finger amputation, penile 
amputation, ulcers, gangrene, cardiovascular 
risk, and cost analysis); dialysis not 
mentioned in the title; comparing prognosis 
and outcomes of various interventions; case 
reports; being not focused on dialysis patients as a 
cohort
Full text screened
(n = 7)
Abstracts screened 
(n = 20)
Records excluded
(n = 13)
Reasons: case studies (n = 2); review articles
(n = 6); only including subset of dialysis
patients (who underwent free tissue transfer,
dialysis patients with symptomatic limb
ischemia) (n = 2); not including dialysis
patients (n = 1); assessing vascular changes as
an outcome in amputated limbs (n = 1);
assessing the prognosis of percutaneous
transluminal angioplasty as an outcome (n = 1)
Records excluded 
(n = 1)
Reasons: full text was not available online 
Literature included in systematic review
(n = 6)
Figure 1: Flow diagram to illustrate the studies identified for this review.
Five of the studies were longitudinal cohort studies,
out of which four were retrospectively designed [19, 21,
22, 24] and one of each of prospective longitudinal format
[23] and observational case-control study [20], respectively.
Although all the studies were investigated for comorbidities
in the participant population, there were some variations in
the different studies. The prevalence of comorbidities also
varied from study to study; for example, only 4.4% [23]
of participants in one study had coronary artery disease
compared to 54% in another [21]. All the retrospective studies
collected their data via databases or medical chart review.
Locking-Cusolito and colleagues used a foot assessment
instrument which was used in clinics to collect data from
patients attending their clinic [20].The prospective study had
a follow-up time period of 96 months over which the data
was collected via direct patient contact, medical charts, or
telephonic interview.
3.3. Amputation in Subjects on Renal Dialysis. The reported
finding on prevalence of amputation in patients with renal
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Table 2: Summary of studies assessing risk factors of amputation in
subjects on renal dialysis.
Author Risk factors for amputation in all dialysispatients
Speckman et
al., 2004 [19]
MUR < 58.5%: HR 2.4 (CI 1.4–4.2), 𝑝 < 0.01
CVD: HR 2.4 (CI 1.6–3.7), 𝑝 < 0.001
Combe et al.,
2009 [22]
DM: AOR 5.55 (CI 4.63–6.64), 𝑝 < 0.001
Men: AOR 1.82 (CI 1.61–2.06), 𝑝 < 0.001
Blacks: AOR 1.45 (CI 1.28–1.65), 𝑝 < 0.001
Smoking: AOR 1.22 (CI 1.03–1.43), 𝑝 < 0.001
Retinopathy: AOR 1.78 (CI 1.55–2.04),
𝑝 < 0.001
Peripheral neuropathy: AOR 2.25 (CI
1.98–2.56), 𝑝 < 0.001
Calciphylaxis: AOR 2.37 (CI 1.63–3.45),
𝑝 < 0.001
Plantinga et
al., 2009 [24]
DM: RH 4.33 (CI 2.98–6.30), 𝑝 < 0.05
PVD: RH 1.59 (CI 1.17–2.15), 𝑝 < 0.05
CRP: RH 2.7 (CI 1.72–4.23), 𝑝 < 0.05
Albumin < 3.3 g/dL: RH 0.63 (CI 0.42–0.94),
𝑝 < 0.05
Locking-
Cusolito et
al., 2005 [20]
DM: AOR 10.17 (CI 3.7–27.7), 𝑝 < 0.001
Ishii et al.,
2012 [23]
DM: HR 5.29 (CI 2–13.9), 𝑝 = 0.0008
CRP: HR 1.01 (CI 1–1.02), 𝑝 < 0.05
Reddy et al.,
2007 [21]
Dialysis > 12 months: AOR 2.74 (CI 1.22–6.16),
𝑝 < 0.05
DM, diabetes mellitus; HR, hazard ratio; RH, relative hazard; AOR, adjusted
odds ratio; PVD, peripheral vascular disease; CVD, cardiovascular disease;
MUR, mean urea reduction; CI: 95% confidence interval.
failure on renal dialysis was 1.7% to 13.4% (Table 1). Five
out of the six studies that were included in the systematic
review identified presence of diabetes mellitus as the leading
risk factor for amputation (𝑝 < 0.05) [19, 20, 22–24].
Although all the studies used different ratios to present their
findings, there were two studies which used hazard ratios
(HR). Ishii and colleagues and Speckman and colleagues
reported that diabetic renal failure patients had a higher
risk of getting amputation as compared to their counterparts
without diabetes, HR 5.29, 95% CI 2–13.9, 𝑝 = 0.0008, and
HR 7.4, 95% CI 4.1–13.5, 𝑝 < 0.001, respectively. On the
other hand, Reddy and colleagues investigated the association
of duration of renal replacement therapy and amputation as
an outcome. They found that a higher percentage (19%) of
established haemodialysis patients (dialysis for ≥12 months)
had to have amputation as compared to new haemodialysis
patients (8%) (dialysis for ≤3 months) (𝑝 = 0.01) [21].
3.4. Risk Factors of Amputation in Subjects on Renal Dialysis.
Detailed risk factors are shown in Table 2. Diabetes was
reported as a leading risk factor associated with amputation
in renal dialysis patients in 5 out of the 6 studies. Two studies
compared diabetic andnondiabetic subjects on dialysis show-
ing higher rate of amputation amongst diabetics as shown in
Table 3.
Other amputation risk factors reported in subjects on
renal dialysis included longer duration of dialysis therapy,
HbA1c levels, c-reactive protein (CRP), and low serum
albumin. In patients with diabetes, a higher HbA1c level
after commencement of dialysis was found to be statistically
significant as a risk factor for amputation [20, 23]. Ishii
and colleagues established that all patients requiring major
amputation (𝑛 = 7) were found to fall in the highest HbA1c
quartile (HbA1c > 6.8%). Overall, 6.1% of all amputees had
an HbA1c > 6.8% as compared to only 0.9% of amputees
with HbA1c < 5.4%. The association of a higher HbA1c
and amputation was also found to be statistically significant:
HbA1c > 6.8%, HR 2.99, 95% CI 1.17–7.7, 𝑝 = 0.023. A higher
CRP level, as a marker of inflammation, was found to be
related to amputation by Ishii and colleagues, HR 1.01, 95%CI
1–1.02, 𝑝 = 0.047, and by Plantinga and colleagues showing
relative hazard (RH) 2.7, 95% CI 1.72–4.23, 𝑝 < 0.05 [24].
Subjects on renal dialysis with a low mean serum albumin
(<3.3 g/dL) were also found to be at risk of amputation by
Speckman and colleagues: HR 1.8, 95% CI 1.1–3, 𝑝 < 0.05.
If these subjects had diabetes, the risk was further increased:
HR 3.8, 95%CI 1.1–12.5,𝑝 < 0.05. In the same study, Plantinga
et al. reported increased albumin levels were associated with
significantly decreased risk of amputation: RH 0.63, 95% CI
0.42–0.94, 𝑝 < 0.05 [24].
4. Discussion
This review highlights the scarcity of literature which inves-
tigates the prevalence and risk factors of amputation in
patients with ESRF on renal dialysis. It revealed 1.7% to
13.4% as prevalence of LLA in patients receiving renal dialysis
therapy [20, 23]. This showed a wide variation in amputation
between studies and countries. For instance, study from
Japan reported lower prevalence of LLA in subjects on
renal dialysis compared to higher rate in USA and Canada.
This variation could suggest a better outcome amongst the
Japanese cohort. This is in keeping with the finding of lower
rate of coronary artery disease in the population, which
is identified as an important risk factor for LLA [1, 2, 7].
It could also suggest that North Americans have a lower
threshold for LLA. Other reasons for the wide variation in
prevalence might be due to multiple factors. For instance,
Combe and colleagues conducted a large scale multinational,
multicentre study which included a large number of subjects
(29838) and investigated various associated risk factors such
as age, ethnicity, calciphylaxis, retinopathy, and neuropathy
[22]. However, the methodology used to collect the data
did not differentiate between types of amputation. Though
this study presented an overall worldwide 6% prevalence of
amputation in renal dialysis patients, it may have been an
overestimation. Plantinga and colleagues on the other hand
excluded digital amputation from their data collection; this
might have resulted in an underestimation of all amputations
in renal dialysis patients [24]. Nevertheless, these findings
warrant further studies.
Interestingly, we have identified presence of diabetes as
an important single risk factor for LLA, with up to 26.5%
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Table 3: Summary of studies assessing risk factors of amputation in diabetic and nondiabetic patients on dialysis.
Author Total patientswith DM
DM patients
having
amputation
Risk factors for amputation
in patients with DM
Total
non-DM
patients
Non-DM
patients
having
amputation
Risk factors for
amputation in
patients without DM
Speckman et
al., 2004 [19] 1751 104 (6%)
CVD: HR 1.7 (CI 1.1–2.6),
𝑝 < 0.05
MUR < 58.5%: HR 2.6 (CI
1.4–4.8), 𝑝 < 0.01
1469 12 (1%)
Increasing age: HR
1.09 (CI 1.02–1.2),
𝑝 < 0.01
Mean serum albumin
< 3.5 g/dL: HR 3.8 (CI
1.1–12.5), 𝑝 < 0.01
Combe et al.,
2009 [22] 11129 14.2%
Peripheral neuropathy:
AOR 2.23 (CI 1.94–2.56),
𝑝 < 0.001
Calciphylaxis: AOR 2.02
(CI 1.32–3.1), 𝑝 < 0.001
Men: AOR 1.69 (CI
1.48–1.94), 𝑝 < 0.001
18203 1.60%
Calciphylaxis: AOR
3.41 (CI 1.74–6.7),
𝑝 < 0.001
Men: AOR 2.56 (CI
1.86–3.51), 𝑝 < 0.001
Blacks: AOR 1.88 (CI
1.23–2.86), 𝑝 < 0.001
Smoking: AOR 1.62
(CI 1.11–2.37),
𝑝 < 0.001
DM, diabetes mellitus; HR, hazard ratio; RH, relative hazard; AOR, adjusted odds ratio; CVD, cardiovascular disease; MUR, mean urea reduction; CI: 95%
confidence interval.
of patients with diabetes receiving renal dialysis having
amputation [20]. Renal dialysis has been found to increase
the risk of foot ulcer in patients with diabetes.This significant
temporal association is suggested by a 3 times higher risk of
having foot ulcer in the first year of starting dialysis therapy
and an almost 32 times higher risk for major amputation
in the first year of starting dialysis therapy [26–28]. This
risk is further increased in the presence of elevated CRP
[23, 24] and low serum albumin [19, 24] as well as high
HbA1c level [20, 23] at the onset of dialysis in agreement
with recent reports [27, 28], suggesting that acute phase
reactants and poor control of diabetes worsen the prognosis
further. These findings were suggested from studies which
were limited to patients on haemodialysis [19–23]. On the
other hand, the only study which included both peritoneal
dialysis and haemodialysis [24] reported a high prevalence of
limb amputation of 13%; however, the authors did not provide
a comparison between patients receiving haemodialysis and
those on peritoneal dialysis.
Although studies have shown that peripheral arterial dis-
ease is common amongst patients on chronic dialysis therapy,
the indication for bypass surgery in these patients is still a
controversial topic. This is due to the high morbidity and
mortality rates of these patients. Even though PTA is con-
sidered a possible procedure to treat critical limb ischemia,
there is limited literature available on the prognosis of this
intervention. In a 2-year follow-up prospective study on
haemodialysis patients with diabetic foot wounds who were
treated with PTA and minor amputation, it was found that
only 41.9% of patients survived without reamputation with a
2-year postoperative mortality rate of 38.7% [29]. This study
had a small sample size of 31 haemodialysis patients; hence,
it is important to explore the prognosis of PTA as treatment
and prevention of amputation by doing more studies with
a larger sample size. Other aspects of the review include asso-
ciations between surgical procedures for vascular access and
amputation. In patients with and without diabetes, both vari-
ables were increased after initiation of haemodialysis ther-
apy. Amputations, which are potentially preventable, were
associated with significant mortality amongst haemodialysis
patients [30]. Thus, early interventions at primary care level
have been found to lower the rate of foot complications and
amputation, further stressing the need for multidisciplinary
care in order to prevent adverse outcome in this group of
population [31].
5. Conclusion
This review has demonstrated the high rate of lower limb
amputation in patients with ESRF receiving dialysis therapy.
It has also identified the risk factors associated with an
adverse outcome, the chief amongst them being presence
of diabetes. Other identified risk factors include hypoalbu-
minemia and elevated CRP. Thus, with early intervention
in diabetic subjects, many limbs would likely be salvaged
and the overall rate of adverse outcome from LLA would
eventually be lowered. However, there is still a limited
literature on preventative programs for LLA in subjects on
renal dialysis. Furthermore, association between peritoneal
dialysis and LLA is scanty as most studies were conducted on
haemodialysis subjects. More studies are needed to further
characterise findings in these areas.
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